Targeted immune‑modulating therapy to reduce graft‑versus‑host disease (GVHD) risk after allogeneic hematopoietic stem cell transplantation. Designed to fine‑tune immune responses for autoimmune and inflammatory diseases, improving patient outcomes and expanding transplant applicability.